ERBB2 and neoplasm: We observed that there were no significant differences in killing ability between VL-CAR-T cells and other CAR-T groups in the first three rounds of stimulation, while there was a significant increase in tumor lysis in the VL-CAR-T cells to HER2+ target cells compared to scFv-based CAR-T cells (Figure 4B).